Across TCGA pan-cancer cohorts, IGHV1-24 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV1-24 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IGHV1-24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV1-24 expression acts as an unfavorable survival marker.

OV and LUAD are the cancer types where IGHV1-24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.311	0.691	.042	12	view →
LUAD	OS	Median	III,IV	0.131	0.669	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGHV1-24 tumor-vs-normal RNA expression · all IGHV1-24 data types